Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 1Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Dianhydrogalactitol × Clear all
NCT01478178 2025-08-29

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Kintara Therapeutics, Inc.

Phase 1/2 Completed
55 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡